Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost.

Abstract

Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis. High vascular resistance in PAH arises from an imbalance between vasodilatory mediators (prostacyclin, NO) and vasoconstrictive mediators (endothelin, thromboxane A-2). Inhaled iloprost and the dual endothelin receptor antagonist bosentan have recently been shown to be effective in controlled clinical trials. Our case report demonstrates that patients with bosentan-refractory PAH can be successfully treated with iloprost inhalation.

• Authors: K Ahmadi-Simab, P Lamprecht, W L Gross
• Journal: Clinical and experimental rheumatology (Clin Exp Rheumatol) 2005 May-Jun Vol. 23 Issue 3 Pg. 402-3 ISSN: 0392-856X [Print] Italy
• PMID: 15971433 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antihypertensive Agents
• Sulfonamides
• Vasodilator Agents
• Iloprost
• Bosentan

Topics

• Administration, Inhalation
• Antihypertensive Agents (therapeutic use)
• Bosentan
• Exercise Test (drug effects)
• Female
• Hemodynamics (drug effects, physiology)
• Humans
• Hypertension, Pulmonary (drug therapy, physiopathology)
• Iloprost (administration & dosage)
• Middle Aged
• Pulmonary Artery (pathology)
• Sulfonamides (therapeutic use)
• Treatment Outcome
• Vasodilator Agents (administration & dosage)
• Walking